New drug combo tested to control recurrent ovarian cancer
NCT ID NCT06494150
Summary
This study is testing whether a combination of two drugs—nab-sirolimus and the hormone therapy fulvestrant—can help control recurrent low-grade ovarian cancer. It will enroll 37 patients who have seen their cancer return after prior treatment. Researchers will measure how well the tumors shrink and how long the treatment keeps the cancer from growing, while closely monitoring side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOW GRADE OVARIAN SEROUS ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
OU Health Stephenson Cancer Center
RECRUITINGOklahoma City, Oklahoma, 73117, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.